Biotechnology

Related Outside Content

A pharmaceuticals sector exchange traded fund perked up Friday after Endo International (NasdaqGS: ENDP) Chief Executive Rajiv De Silva stepped aside to be replaced by generics division head Paul Campanelli. The SPDR Pharmaceuticals ETF (NYSEArca: XPH) rose 0.8% Friday. Meanwhile, ENDP shares jumped 16.1% on the shift in management. SEE MORE: M&A Activity, Passing Drug […]

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds have been hindered by presidential politics this year. That is old news. Just look at IBB’s recent price action. The largest biotechnology ETF is residing at its highest levels since January. Investors who are closely watching […]

First Trust has expanded its line of smart beta exchange traded funds with multi-factor sector plays based on attractive valuations, strong momentum and low volatility to help investors focus on portfolio risk management and improved diversification. First Trust has come out with seven new smart-beta sector ETFs, including: First Trust Nasdaq Bank ETF (NasdaqGM: FTXO) […]

Sarepta Therapeutics (NasdaqGS: SRPT) surged Monday and lifted biotechnology-related exchange traded funds after the Food and Drug Administration approved the Duchenne muscular dystrophy drug eteplirsen. Leading the charge in the ETF space on Monday, the BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC) increased 2.2%, PowerShares DWA Healthcare Momentum Portfolio (NYSEArca: PTH) gained 3.8% and SPDR S&P […]

The SPDR S&P Biotech ETF (NYSEArca: XBI), the third-largest biotechnology exchange traded fund by assets, is among the previously high-flying biotech ETFs that have been sapped by politicians, looking to earn voters favor in an election year, attacking high drug prices. Investors who are closely watching the presidential race will want to keep an eye […]

A large acquisition and favorable results from a drug trial helped biotechnology and pharmaceutical sector-related exchange traded funds rally on Monday. Among the best performing ETFs of Monday, the PowerShares Dynamic Biotech & Genome (NYSEArca:PBE) jumped 3.0%, ALPS Medical Breakthroughs ETF (NYSEArca: SBIO) advanced 3.1%, iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) rose 2.7% and SPDR Pharmaceuticals […]

Simply put, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds have been hampered by presidential politics this year, a theme that may not evaporate until after Election Day. IBB, the largest biotech ETF by assets, is heavily allocated to the largest biotech names. For […]

It has not been a typical year for healthcare exchange traded funds such as the Vanguard Health Care ETF (NYSEArca: VHT) and the Health Care Select Sector SPDR (NYSEArca: XLV). Political posturing has been weighing on the S&P 500’s third-largest sector weight, sending biotechnology and some specialty pharmaceuticals stocks tumbling. Last week, Democratic presidential nominee, […]

Democratic presidential nominee, Hillary Clinton, put the spotlight on Mylan (NasdaqGS: MYL) EpiPen prices, triggering a selloff in biotech exchange traded funds and reminding investors of political risks in an election season. Biotech stocks were still reeling from Clinton’s Wednesday remarks, with the iShares Nasdaq Biotechnology ETF (NasdaqGM: IBB) down 3.6% and SPDR S&P Biotech […]

Pfizer (NYSE: PFE) announced a $14 billion deal to acquire cancer drug developer Medivation (NasdaqGS: MDVN), propelling the broader biotechnology exchange traded funds higher on speculation of more deals in the sector. Biopharmaceutical giant Pfizer will pay Medivation shareholders $81.5 per share in cash, or a 21% markup to Medivation’s closing price on Friday of […]

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, and rival biotechnology exchange traded funds, seem to have put the woes experienced earlier this year behind them and recently have been in rally mode. That is prompting a spate of bullish calls on the once downtrodden group. Rare are the occasions […]

The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, is higher by 9% over the past month and that is just one sign that the once downtrodden biotechnology group is rebounding. As IBB and rival biotech ETFs have recently been gaining momentum, perhaps a sign that the group is putting election […]

The BioShares Biotechnology Products Fund (NasdaqGM: BBP) has capitalized on a string of acquisitions and outperformed other biotechnology- and pharmaceuticals-related exchange traded funds. BBP, which follows U.S.-listed biotech companies with a primary product offering or product candidate that has landed FDA approval, gained 4.0% over the past week and increased 9.1% over the past three […]

U.S. equities strengthened Wednesday with biotechnology stocks and sector-related exchange traded funds leading the charge on better-than-expected second quarter results. On Wednesday, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index,rose 2.5%. The SPDR S&P Biotech ETF (NYSEArca: XBI), which follows a more equal weight methodology, gained 3.2% and was testing […]

As the equities market swings, traders have incorporated leveraged and inverse exchange traded funds to jump on short-term opportunities and hedge around events, like the Brexit vote. “If ever there was a market environment for uncertainty hedging, it is now,” Andy O’Rourke, Managing Director and Chief Marketing Officer at Direxion, told ETF Trends on a […]

After a seven year bull run and an increased uncertainty, people may expect the equities market will more likely pullback and give up some of its gains. Consequently, traders have turned to bearish or inverse exchange traded fund strategies to hedge against turns in a more volatile market. On an upcoming webcast this Wednesday, Sector Strategies […]

Biotechnology-related exchange traded funds are stuck in a malaise, with the underlying biotech sector declining for the ninth consecutive session, its longest selloff in a twenty years. Since June 6, the iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), which tracks the Nasdaq Biotechnology Index, declined 10.3%. Related: Hit The Lab With These 17 Biotech ETFs The […]

Janus Capital Group expanded its offerings to include four new exchange traded funds that track various health and living-related themes. Janus rolled out The Health and Fitness ETF (NasdaqGM: FITS), The Long-Term Care ETF (NasdaqGM: OLD), The Organics ETF (NasdaqGM: ORG) and The Obesity ETF (NasdaqGM: SLIM). Each fund comes with a 0.50% expense ratio. […]

Revitalizing the merger and acquisition outlook for biotech sector exchange traded funds, Pfizer (NYSE: PFE) announced it will buy biopharma company Anacor Pharmaceuticals (NasdaqGS: ANAC). Pfizer paid a 55% premium to Anacor’s closing price last Friday for $5.2 billion, gaining control over an experimental eczema treatment crisaborole, which posted strong results in Phase 3 clinical […]

While the health industry has underperformed so far this year, health care stocks and sector-related exchange traded funds can gain momentum on increased merger and acquisition activity. About $144 billion in deals for biotechnology, health care and pharmaceutical companies have been announced this year, with Abbott Laboratories (NYSE: ABT) agreeing to acquire St Jude Medical […]

Biotechnology stocks remain one of worst performing areas that are still stuck in a bear market after failing to recuperate earlier losses in the year, along with the broader market. However, exchange traded fund (ETF) investors still believe in a rebound. The iShares Nasdaq Biotechnology ETF (NasdaqGS: IBB), the largest biotech ETF by assets, declined 17.0% […]

Expensive biologics have weighed on health care consumers. However, as the government tries to contain the soaring costs, a generic drugs-related exchange traded fund could capitalize on the growth of cheaper biosimilars. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global Generics & New Pharma Index, which […]

The health care sector remains one of the worst performing areas of the market, despite the recovery off the Feb. 11 lows. With the earnings season coming up, health care stocks could be one of the few bright spots in the markets and exchange traded funds that track the sector could lead ahead. Based on […]

Pfizer (NasdaqGS: PFE) called off the deal with Allergan (NasdaqGS: AGN) on Wednesday, but there was a silver lining. Exchange traded funds that track the biotechnology sector surged as traders speculated that the two companies could court other merger targets. Biotechnology sector-related ETFs led gains on Wednesday. The BioShares Biotechnology Clinical Trials Fund (NasdaqGM: BBC), […]

As investors gear up for a volatile market in the year ahead, more aggressive exchange traded fund investors have utilized leveraged and inverse products to quickly adapt and capitalize on shifting market conditions. On the upcoming webcast, Tactical Strategies to Combat Market Volatility, Sylvia Jablonski, Managing Director and Co-Head of the Capital Markets & Institutional Strategy […]

Unloved ETF healthcare segment may provide a cheap opportunity for bargain hunters SPDR S&P 500 ETF (NYSEArca: SPY) is up 0.8% so far this year Investors may also be trying to catch a falling knife after the huge sell-off in the biotech sub-sector as biotechs remain in bear market territory Healthcare stocks, notably biotechnology names, […]

ETFs that implement derivative financial tools have drawn greater scrutiny from regulators Leveraged and inverse ETFs are being used as trading products over the short-term  Investors are taking both sides of the trade, or long bullish and short bearish positions during market turns Investors have utilized exchange traded funds that track leveraged and inverse strategies […]

Slow and steady value and conservative sectors are leading market gains RPV was best performing non-leveraged ETF across various Morningstar style categories  Close behind was RZV, which like RPV, targets companies exhibiting a value characteristic Since the start of the bull market, we may come to expect growth stocks like biotechnology and technology-sector exchange traded […]

U.S. regulators approved the sale of a lower-priced copy of an expensive blockbuster biologic drug, paving the way for further biosimilars to hit the market and supporting the outlook for the relatively new generic drugs exchange traded fund. The Market Vectors Generic Drugs ETF (NasdaqGM: GNRX) tries to reflect the performance of the Indxx Global […]

The $3.5 billion First Trust Dorsey Wright Focus 5 ETF (NasdaqGM: FV) has helped exchange traded fund investors target some high-flying sectors, but the momentum strategy recently cut its biotech position for a defensive play. The First Trust Dorsey Wright Focus 5 ETF follows DWA’s relative strength ranking system where sector ETFs are compared to […]